An Open Label Phase 2 Trial to Evaluate the Safety, Tolerability, and Efficacy of Low Dose G-FLIP in Combination With Mitomycin C in Patients With Stage IV Pancreatic Cancer Who Have Failed First-Line Treatment

Trial ID: NCT06233877

Interventional - Phase 2 - Not yet recruiting

The study focuses on advanced metastatic pancreatic cancer, testing a combination of low-dose anti-cancer drugs (G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin) with the addition of Mitomycin C. The aim is to find a safer and more effective therapy for this devastating disease.

Conditions

• Pancreatic Cancer

Interventions

• G-GLIP plus Mitomycin C

Eligibility

Inclusion criteria

• Histologically confirmed metastatic (Stage IV) pancreatic adenocarcinoma.
• Failed first-line chemotherapy.
• ECOG performance status of 0-2.
• Expected survival of more than 3 months.
• Adequate organ function as indicated by lab values.
• Age 18 or older.
• Signed informed consent.

Exclusion criteria

• • Known brain metastases.
• Significant cardiovascular or other uncontrolled diseases.
• Pregnant or breastfeeding women

Sponsor

Hirschfeld Oncology

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows